Tags : Parkinson’s Disease


STADA Expands its Specialty Footprint with the Acquisition of Lobsor

Shots:   STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries Levodopa, carbidopa and […]Read More


Biogen Signs an Agreement with Denali on LRRK2 Program for

Shots: Denali to receive $560M up front, $465M as equity investment at a price of $34.94/ share, representing 11.2% of Denali’s Pro-forma outstanding stock along with $1.125B as milestones. The two companies will codevelop Denali’s LRRK2 inhibitor for PD and co-commercialize it in the US and China while Biogen has the right to commercialize the […]Read More

Pharma Regulatory

Kyowa Kirin’s Nourianz (istradefylline) Receives FDA’s Approval as an Adjunctive

Shots: The US FDA has granted approval to Nourianz for use as an add-on treatment to levodopa/carbidopa and is based on clinical studies assessing Nourianz vs PBO in PD patients experiencing “OFF” episodes, administering a stable dose of levodopa/carbidopa with/out other PD therapies The four clinical study results demonstrated that adjunct to levodopa/carbidopa, istradefylline improves […]Read More


C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost

Shots: The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the companies on validated targets The focus of the agreement is to advance C4XD drug discovery pipeline by validating targets identified by C4XD’s Taxonomy3 with the […]Read More


Kyowa Kirin Signs an Exclusive Commercialization Agreement with Hisamitsu for

Shots: Hisamitsu to receive upfront, milestone based on the regulatory approval and royalties on sales of product. Kyowa Kirin to get exclusive commercialization rights for Hisamitsu’s HP-3000, post marketing approval in Japan The focus of the agreement is to develop & commercialize therapies for Parkinson’s disease developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology […]Read More